Skip to main content

SEZ6/BSRP-C Antibody (Abbv-011) [FITC]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28127F

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # Abbv-011

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

SEZ6

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Applications for SEZ6/BSRP-C Antibody (Abbv-011) [FITC]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: SEZ6/BSRP-C

Long Name

Seizure Related 6/Brain-specific Receptor-like Protein-C

Alternate Names

BSRP-C, BSRPC

Gene Symbol

SEZ6

Additional SEZ6/BSRP-C Products

Product Documents for SEZ6/BSRP-C Antibody (Abbv-011) [FITC]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SEZ6/BSRP-C Antibody (Abbv-011) [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...